HORMONE AND RADIATION THERAPY IN HIGH- AND VERY HIGH-RISK PATIENTS WITH PROSTATE CANCER
https://doi.org/10.17650/1726-9776-2012-8-4-65-69
Abstract
The prevalence of prostate cancer (PC) is steadily growing every year. In the Russian Federation, its peak morbidity is in the age group of 70 years. Some patients refuse surgery or have contraindications because of comorbidity. Teleradiotherapy in combination with or without hormone therapy is an alternative treatment. The paper analyzes the authors’ results of treating high- and very high-risk patients with PC who received hormone and radiation therapy. The study retrospectively included the data of 132 patients who had been allocated to 3 groups according to the duration of adjuvant hormone therapy. The treatment results were assessed over a 5-year follow-up period according the following parameters: a lower decreased prostate-specific antigen (PSA) score, recurrence rate, and 5-year relapse-free survival determined the by PSA level.
About the Authors
A. O. Karyakin
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
Yu. V. Gumenetskaya
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
N. A. Gorban
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
N. G. Minayeva
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
O. B. Karyakin
Medical Radiology Research Center, Ministry of Health of Russia, Obninsk
Russian Federation
Russian Federation
References
1. Злокачественные новообразования в России в 2010 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012.
2. European Association of Urology. Guidelines. 2012. P. 46−49.
3. Bolla M., Collette L., van Tienhoven G. et al. Ten year results of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy; a phase III EORTC study. Int J Radiat Oncol Biol Phys 2008; 72(1 Suppl.1):30−1.
4. Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinomalong-term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285−90.
5. Bolla M., de Reijke T.M., van Tienhoven G. et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT: Results of the randomized EORTC Phase III trial 22961. J Clin Oncol 2007;25:238 (abstr. 5014).
6. Antonarakis E.S., Blackford A.L., Garrett-Mayer E., Eisenberger M.A. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol 2007;25(31): 4998−5008.
Review
For citations:
Karyakin A.O., Gumenetskaya Yu.V., Gorban N.A., Minayeva N.G., Karyakin O.B. HORMONE AND RADIATION THERAPY IN HIGH- AND VERY HIGH-RISK PATIENTS WITH PROSTATE CANCER. Cancer Urology. 2012;8(4):65-69. (In Russ.) https://doi.org/10.17650/1726-9776-2012-8-4-65-69
Views:
966
Email this article 